PMS Registry
Company Name
Astellas Pharma Taiwan, Inc.
Protocol Number
9463-MA-1006
Title of Study
Non-interventional Study on the Safety and Efficacy of Micafungin for Prevention and Treatment of Fungal Infections in Pediatric Patients in Asia/Oceania – ERADICATE Study
Primary Objective
The primary objective of this study is to evaluate the safety of micafungin when prescribed for prophylaxis or treatment of fungal infections in paediatric patients in Asia/Oceania.
Number of Sites
6 sites in Taiwan
Period of Study
From:December, 2016 to:November, 2019
Number of Patients
120人
IRB Approval Date
TBC
Publication Plan / Date
TBC